Aurobindo Pharma transfers domestic formulations biz to subsidiary for ₹143.21 Cr

Board & Shareholder Meetings View source PDF

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.4%1-day move

₹1336.00

prior close

₹1344.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.1-0.7-1.0-1.1-0.4-0.1+0.2+1.2+0.3+3.9+6.7+10.9+8.2+19.3

Up moveDown movePending

AI summary

Aurobindo Pharma's Board approved transferring its domestic branded generic pharmaceutical formulations business to wholly owned subsidiary Auropharm Limited for a lump sum of ₹143.21 Crores. The business contributed 0.55% (₹175.34 Cr) of consolidated turnover and 0.45% of net worth. Deal expected to close in 90-120 days, with economic benefits transferred from April 1, 2026. No impact on consolidated financials as buyer is a wholly owned subsidiary. No change in shareholding.

Likely market impact

Minor restructuring within group; no consolidated financial impact. Aims to accelerate domestic business growth and improve operational efficiency.